We are live on ! Find out more
HRTX icon

Heron Therapeutics

Positive
Neutral
Negative
Sentiment 3-Months
Positive 22.2%
Neutral 44.4%
Negative 33.3%

Negative
Zacks Investment Research
8 hours ago
New Strong Sell Stocks for July 15th
BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.
New Strong Sell Stocks for July 15th
Neutral
GlobeNewsWire
1 month ago
U.S. District Court Issues Decision Regarding CINVANTI® Patents
CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.
U.S. District Court Issues Decision Regarding CINVANTI® Patents
Neutral
Seeking Alpha
2 months ago
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Positive
MarketBeat
2 months ago
Heron Therapeutics Q1 Earnings Call Highlights
Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.
Heron Therapeutics Q1 Earnings Call Highlights
Positive
Zacks Investment Research
2 months ago
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
Negative
Zacks Investment Research
2 months ago
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates.
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Negative
Zacks Investment Research
2 months ago
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Neutral
GlobeNewsWire
2 months ago
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights.
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
Positive
Zacks Investment Research
3 months ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar